Mizuho Securities Sticks to Their Buy Rating for Atara Biotherapeutics (ATRA)

According to TipRanks, Syed is an analyst with an average return of -1.0% and a 42.91% success rate. Syed covers the Healthcare sector, focusing on stocks such as Century Therapeutics, Atara Biotherapeutics, and Assembly Biosciences.

Atara Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $13.67.

Based on Atara Biotherapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $516 thousand and a GAAP net loss of $4.15 million. In comparison, last year the company earned a revenue of $98.15 million and had a net profit of $38.01 million

Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ATRA in relation to earlier this year. Last month, Yanina Grant-Huerta, the CAO of ATRA sold 2,414.00 shares for a total of $22,015.68.